Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

Because of the dual attack modality, these agents are more effective than traditional therapies at aiding the immune system to find and kill multiple myeloma cells. Moreover, as the website stated, ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

Hamlet Gasoyan, MD, discusses some of the common challenges that oncologists face when getting patients started on more ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with ...